Download Traffic Light Comment - West Suffolk Clinical Commissioning Group

Ipswich and East Suffolk Clinical Commissioning Group
West Suffolk Clinical Commissioning Group
Traffic Light Comment (TLC) Form
Drug
Indication
Dulaglutide (Trulicity®)
Glucagon-like-peptide-1 receptor agonist
(GLP-1)
Type II Diabetes Mellitus
NICE TA (if applicable) and date released
Date of COG meeting where this traffic light
rating was discussed:
09 May 2016
N/A
New drug
√
New indication for an
existing drug
Review of existing traffic light rating
Existing traffic light rating is …..………..…..
Comments from:
Dr. John Clark, Consultant Diabetologist and Endocrinologist, West Suffolk Hospital NHS Foundation
Trust
Date: April 2016
Traffic Light Recommendation:
Green – Hospital initiated and first prescription provided by hospital, then GP prescribed
Reason for recommendation:
In line with NICE guidance Type 2 diabetes in adults: management December 2015 and WSCCG Type
2 Diabetes Mellitus Adult Treatment Pathway March 2016, initial discussions with Dr. John Clark
suggested that dulaglutide (Trulicity®) alongside other glucagon-like-peptide-1 receptor agonists should
be assigned a green drug status on the WSCCG traffic light system i.e. Hospital initiated and first
prescription provided by hospital, then GP prescribed.
The reason being that this would support GPs to seek up-to-date appropriate advice on injectable from
the Community Diabetes Nursing Services (CDNS) specialist prior to treatment initiation by taking into
account patient’s individual needs and preferences.
Comments from:
WSCCG Prescribing Workstream
Date: 27 April 2016
Traffic Light Recommendation:
Green – Hospital initiated and first prescription provided by hospital, then GP prescribed
Reason for recommendation:
In line with NICE guidance Type 2 diabetes in adults: management December 2015 and WSCCG Type
2 Diabetes Mellitus Adult Treatment Pathway March 2016, discussions at the Prescribing Workstream
suggested an agreement with Dr. Clark’s comments and support for dulaglutide (Trulicity®) alongside
other glucagon-like-peptide-1 receptor agonists to be assigned a green drug status on the WSCCG
traffic light system.
It was agreed that this would support GPs to seek up-to-date appropriate advice on injectable from the
Community Diabetes Nursing Services (CDNS) specialist prior to treatment initiation by taking into
account patient’s individual needs and preferences.
Developed by the Medicines Management Team, West Suffolk CCG, September 2015, draft version 1